ABSTRACT
Glucocorticoids (GCs) are anti-inflammatory and immunosuppressive steroid molecules secreted by the adrenal gland and regulated by the hypothalamic-pituitary-adrenal (HPA) axis. GCs present a circadian release pattern under normal conditions; they increase their release under stress conditions. Their mechanism of action can be via the receptor-independent or receptor-dependent pathway. The receptor-dependent pathway translocates to the nucleus, where the ligand-receptor complex binds to specific sequences in the DNA to modulate the transcription of specific genes. The glucocorticoid receptor (GR) and its endogenous ligand cortisol (CORT) in humans, and corticosterone in rodents or its exogenous ligand, dexamethasone (DEX), have been extensively studied in breast cancer. Its clinical utility in oncology has mainly focused on using DEX as an antiemetic to prevent chemotherapy-induced nausea and vomiting. In this review, we compile the results reported in the literature in recent years, highlighting current trends and unresolved controversies in this field. Specifically, in breast cancer, GR is considered a marker of poor prognosis, and a therapeutic target for the triple-negative breast cancer (TNBC) subtype, and efforts are being made to develop better GR antagonists with fewer side effects. It is necessary to know the type of breast cancer to differentiate the treatment for estrogen receptor (ER)-positive, ER-negative, and TNBC, to implement therapies that include the use of GCs.
Subject(s)
Glucocorticoids , Triple Negative Breast Neoplasms , Humans , Glucocorticoids/therapeutic use , Glucocorticoids/metabolism , Glucocorticoids/pharmacology , Dexamethasone/pharmacology , Ligands , Hydrocortisone/metabolism , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolismABSTRACT
Kidney injury molecule-1 (KIM-1)/T cell Ig and mucin domain-containing protein-1 (TIM-1) is upregulated more than other proteins after AKI, and it is highly expressed in renal damage of various etiologies. In this capacity, KIM-1/TIM-1 acts as a phosphatidylserine receptor on the surface of injured proximal tubular epithelial cells, mediating phagocytosis of apoptotic cells, and it may also act as a costimulatory molecule for immune cells. Despite recognition of KIM-1 as an important therapeutic target for kidney disease, the regulators of KIM-1 transcription in the kidney remain unknown. Using a bioinformatics approach, we identified upstream regulators of KIM-1 after AKI. In response to tubular injury in rat and human kidneys or oxidant stress in human proximal tubular epithelial cells (HPTECs), KIM-1 expression increased significantly in a manner that corresponded temporally and regionally with increased phosphorylation of checkpoint kinase 1 (Chk1) and STAT3. Both ischemic and oxidant stress resulted in a dramatic increase in reactive oxygen species that phosphorylated and activated Chk1, which subsequently bound to STAT3, phosphorylating it at S727. Furthermore, STAT3 bound to the KIM-1 promoter after ischemic and oxidant stress, and pharmacological or genetic induction of STAT3 in HPTECs increased KIM-1 mRNA and protein levels. Conversely, inhibition of STAT3 using siRNAs or dominant negative mutants reduced KIM-1 expression in a kidney cancer cell line (769-P) that expresses high basal levels of KIM-1. These observations highlight Chk1 and STAT3 as critical upstream regulators of KIM-1 expression after AKI and may suggest novel approaches for therapeutic intervention.
Subject(s)
Acute Kidney Injury/metabolism , Cell Adhesion Molecules/metabolism , Membrane Glycoproteins/metabolism , Protein Kinases/metabolism , Receptors, Virus/metabolism , STAT3 Transcription Factor/metabolism , Acute Kidney Injury/genetics , Acute Kidney Injury/therapy , Animals , Cell Adhesion Molecules/genetics , Cell Line , Checkpoint Kinase 1 , Computational Biology , DNA Damage , Gene Expression Regulation , Hepatitis A Virus Cellular Receptor 1 , Humans , Kidney/metabolism , Male , Membrane Glycoproteins/genetics , Oxidative Stress , Phosphorylation , Promoter Regions, Genetic , Protein Binding , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Rats , Rats, Wistar , Receptors, Virus/genetics , Reperfusion Injury/genetics , Reperfusion Injury/metabolism , STAT3 Transcription Factor/antagonists & inhibitors , STAT3 Transcription Factor/geneticsABSTRACT
The heat shock protein 90 kDalpha (Hsp90) subfamily is constituted by five isoforms, among them Hsp90alpha and Hsp90beta are the more abundant cytosolic proteins. These two proteins are molecular chaperons that participate in numerous cellular processes, through interacting with more than 100 proteins known as client proteins of Hsp90. These client proteins include: transcriptional factors, kinase proteins and other proteins that participate in transcriptional and transductional regulation such as steroid hormone receptors and nitric oxide synthases. This review offers a retrospective in the recent information about molecular and cellular functions of Hsp90 in the vascular physiology. In addition, the studies that evaluate Hsp90 role in the renal physiology and pathophysiology are discussed. Finally, the molecular tools developed to manipulate the Hsp90 expression in vitro and in vivo, through its inhibition or over-expression are reviewed. All these studies together have allowed increasing our knowledge regarding the role of Hsp90 during normal and pathophysiological conditions.
